-
1
-
-
84984537585
-
Trends in elevated triglyceride in adults: United States, 2001-2012
-
Carroll M, Kit B, Lacher D. Trends in elevated triglyceride in adults: United States, 2001-2012. NCHS Data Brief. 2015;198:1-8.
-
(2015)
NCHS Data Brief
, vol.198
, pp. 1-8
-
-
Carroll, M.1
Kit, B.2
Lacher, D.3
-
2
-
-
38949171001
-
Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial
-
1:CAS:528:DC%2BD1cXitVWlsb0%3D 18279736
-
Miller M, Cannon CP, Murphy SA, Qin J, Ray KK, Braunwald E. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol. 2008;51:724-30.
-
(2008)
J Am Coll Cardiol
, vol.51
, pp. 724-730
-
-
Miller, M.1
Cannon, C.P.2
Murphy, S.A.3
Qin, J.4
Ray, K.K.5
Braunwald, E.6
-
3
-
-
84930025596
-
Fasting triglycerides predict recurrent ischemic events in patients with acute coronary syndrome treated with statins
-
1:CAS:528:DC%2BC2MXpt1Kqur4%3D 26022813
-
Schwartz GG, Abt M, Bao W, DeMicco D, Kallend D, Miller M, Mundl H, Olsson AG. Fasting triglycerides predict recurrent ischemic events in patients with acute coronary syndrome treated with statins. J Am Coll Cardiol. 2015;65:2267-75.
-
(2015)
J Am Coll Cardiol
, vol.65
, pp. 2267-2275
-
-
Schwartz, G.G.1
Abt, M.2
Bao, W.3
DeMicco, D.4
Kallend, D.5
Miller, M.6
Mundl, H.7
Olsson, A.G.8
-
4
-
-
84925469494
-
Genetics and causality of triglyceride-rich lipoproteins in atherosclerotic cardiovascular disease
-
1:CAS:528:DC%2BC2cXitFOns7zO 25500239
-
Rosenson RS, Davidson MH, Hirsh BJ, Kathiresan S, Gaudet D. Genetics and causality of triglyceride-rich lipoproteins in atherosclerotic cardiovascular disease. J Am Coll Cardiol. 2014;64:2525-40.
-
(2014)
J Am Coll Cardiol
, vol.64
, pp. 2525-2540
-
-
Rosenson, R.S.1
Davidson, M.H.2
Hirsh, B.J.3
Kathiresan, S.4
Gaudet, D.5
-
5
-
-
84908397421
-
National Lipid Association recommendations for patient-centered management of dyslipidemia: Part 1 - Executive summary
-
25234560
-
Jacobson TA, Ito MK, Maki KC, Orringer CE, Bays HE, Jones PH, McKenney JM, Grundy SM, Gill EA, Wild RA, et al. National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1 - executive summary. J Clin Lipidol. 2014;8:473-88.
-
(2014)
J Clin Lipidol
, vol.8
, pp. 473-488
-
-
Jacobson, T.A.1
Ito, M.K.2
Maki, K.C.3
Orringer, C.E.4
Bays, H.E.5
Jones, P.H.6
McKenney, J.M.7
Grundy, S.M.8
Gill, E.A.9
Wild, R.A.10
-
6
-
-
84866895220
-
Hypertriglyceridemia-induced recurrent acute pancreatitis: A case-based review
-
22276267 3263185
-
Kota SK, Kota SK, Jammula S, Krishna SV, Modi KD. Hypertriglyceridemia-induced recurrent acute pancreatitis: a case-based review. Indian J Endocrinol Metab. 2012;16:141-3.
-
(2012)
Indian J Endocrinol Metab
, vol.16
, pp. 141-143
-
-
Kota, S.K.1
Kota, S.K.2
Jammula, S.3
Krishna, S.V.4
Modi, K.D.5
-
7
-
-
84906937463
-
The polygenic nature of hypertriglyceridaemia: Implications for definition, diagnosis, and management
-
1:CAS:528:DC%2BC2cXhvF2lsrjJ 24731657
-
Hegele RA, Ginsberg HN, Chapman MJ, Nordestgaard BG, Kuivenhoven JA, Averna M, Boren J, Bruckert E, Catapano AL, Descamps OS, et al. The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. Lancet Diabetes Endocrinol. 2014;2:655-66.
-
(2014)
Lancet Diabetes Endocrinol
, vol.2
, pp. 655-666
-
-
Hegele, R.A.1
Ginsberg, H.N.2
Chapman, M.J.3
Nordestgaard, B.G.4
Kuivenhoven, J.A.5
Averna, M.6
Boren, J.7
Bruckert, E.8
Catapano, A.L.9
Descamps, O.S.10
-
8
-
-
84902576469
-
2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines
-
24239923
-
Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63:2889-934.
-
(2014)
J Am Coll Cardiol
, vol.63
, pp. 2889-2934
-
-
Stone, N.J.1
Robinson, J.G.2
Lichtenstein, A.H.3
Bairey Merz, C.N.4
Blum, C.B.5
Eckel, R.H.6
Goldberg, A.C.7
Gordon, D.8
Levy, D.9
Lloyd-Jones, D.M.10
-
9
-
-
84978901996
-
-
AstraZeneca Accessed 24 Nov 2015
-
AstraZeneca. Crestor US prescribing information. Available at: http://www1.astrazeneca-us.com/pi/crestor.pdf. Accessed 24 Nov 2015.
-
Crestor US Prescribing Information
-
-
-
11
-
-
33947118734
-
Safety considerations with niacin therapy
-
1:CAS:528:DC%2BD2sXjtFGlt7c%3D 17368274
-
Guyton JR, Bays HE. Safety considerations with niacin therapy. Am J Cardiol. 2007;99:22c-31c.
-
(2007)
Am J Cardiol
, vol.99
, pp. 22c-31c
-
-
Guyton, J.R.1
Bays, H.E.2
-
13
-
-
84941747401
-
Long-chain omega-3 fatty acids, fibrates and niacin as therapeutic options in the treatment of hypertriglyceridemia: A review of the literature
-
1:CAS:528:DC%2BC2MXhtVeisbjE 26296750
-
Ito MK. Long-chain omega-3 fatty acids, fibrates and niacin as therapeutic options in the treatment of hypertriglyceridemia: a review of the literature. Atherosclerosis. 2015;242:647-56.
-
(2015)
Atherosclerosis
, vol.242
, pp. 647-656
-
-
Ito, M.K.1
-
14
-
-
84873089854
-
-
GlaxoSmithKline Accessed: 24 Nov 2015
-
GlaxoSmithKline. Lovaza prescribing information. Available at: https://www.gsksource.com/gskprm/htdocs/documents/LOVAZA-PI-PIL.PDF. Accessed: 24 Nov 2015
-
Lovaza Prescribing Information
-
-
-
15
-
-
84978902006
-
-
Trygg Pharma Accessed: 24 Nov 2015
-
Trygg Pharma. Omtryg prescribing information. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2014/204977s000lbl.pdf. Accessed: 24 Nov 2015
-
Omtryg Prescribing Information
-
-
-
16
-
-
84978867217
-
-
Amarin Corporation Accessed: 24 Nov 2015
-
Amarin Corporation. Vascepa prescibing information. Available at: www.vascepa.com/full-prescribing-information.pdf. Accessed: 24 Nov 2015
-
Vascepa Prescibing Information
-
-
-
17
-
-
84978836512
-
-
AstraZeneca Accessed: 24 Nov 2015
-
AstraZeneca. Epanova prescribing information. Available at: http://www1.astrazeneca-us.com/pi/epanova.pdf. Accessed: 24 Nov 2015
-
Epanova Prescribing Information
-
-
-
18
-
-
0031425356
-
Safety and efficacy of Omacor in severe hypertriglyceridemia
-
1:STN:280:DyaK1M%2FotFaluw%3D%3D 9865671
-
Harris WS, Ginsberg HN, Arunakul N, Shachter NS, Windsor SL, Adams M, Berglund L, Osmundsen K. Safety and efficacy of Omacor in severe hypertriglyceridemia. J Cardiovasc Risk. 1997;4:385-91.
-
(1997)
J Cardiovasc Risk
, vol.4
, pp. 385-391
-
-
Harris, W.S.1
Ginsberg, H.N.2
Arunakul, N.3
Shachter, N.S.4
Windsor, S.L.5
Adams, M.6
Berglund, L.7
Osmundsen, K.8
-
19
-
-
0032917836
-
Correlation of serum triglyceride and its reduction by omega-3 fatty acids with lipid transfer activity and the neutral lipid compositions of high-density and low-density lipoproteins
-
1:CAS:528:DyaK1MXhsVWgtb4%3D 10217357
-
Pownall HJ, Brauchi D, Kilinc C, Osmundsen K, Pao Q, Payton-Ross C, Gotto AJ, Ballantyne CM. Correlation of serum triglyceride and its reduction by omega-3 fatty acids with lipid transfer activity and the neutral lipid compositions of high-density and low-density lipoproteins. Atherosclerosis. 1999;143:285-97.
-
(1999)
Atherosclerosis
, vol.143
, pp. 285-297
-
-
Pownall, H.J.1
Brauchi, D.2
Kilinc, C.3
Osmundsen, K.4
Pao, Q.5
Payton-Ross, C.6
Gotto, A.J.7
Ballantyne, C.M.8
-
20
-
-
34548319692
-
Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: An 8-week, randomized, double-blind, placebo-controlled study
-
1:CAS:528:DC%2BD2sXhtVemurjN 17825687
-
Davidson MH, Stein EA, Bays HE, Maki KC, Doyle RT, Shalwitz RA, Ballantyne CM, Ginsberg HN. Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study. Clin Ther. 2007;29:1354-67.
-
(2007)
Clin Ther
, vol.29
, pp. 1354-1367
-
-
Davidson, M.H.1
Stein, E.A.2
Bays, H.E.3
Maki, K.C.4
Doyle, R.T.5
Shalwitz, R.A.6
Ballantyne, C.M.7
Ginsberg, H.N.8
-
21
-
-
84893916503
-
Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: The EpanoVa for Lowering Very high triglyceridEs (EVOLVE) trial
-
24528690
-
Kastelein JJ, Maki KC, Susekov A, Ezhov M, Nordestgaard BG, Machielse BN, Kling D, Davidson MH. Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: the EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial. J Clin Lipidol. 2014;8:94-106.
-
(2014)
J Clin Lipidol
, vol.8
, pp. 94-106
-
-
Kastelein, J.J.1
Maki, K.C.2
Susekov, A.3
Ezhov, M.4
Nordestgaard, B.G.5
Machielse, B.N.6
Kling, D.7
Davidson, M.H.8
-
22
-
-
84884355278
-
A highly bioavailable omega-3 free fatty acid formulation improves the cardiovascular risk profile in high-risk, statin-treated patients with residual hypertriglyceridemia (the ESPRIT trial)
-
1:CAS:528:DC%2BC3sXhtlKqs7%2FN 23998969
-
Maki KC, Orloff DG, Nicholls SJ, Dunbar RL, Roth EM, Curcio D, Johnson J, Kling D, Davidson MH. A highly bioavailable omega-3 free fatty acid formulation improves the cardiovascular risk profile in high-risk, statin-treated patients with residual hypertriglyceridemia (the ESPRIT trial). Clin Ther. 2013;35:1400-11.
-
(2013)
Clin Ther
, vol.35
, pp. 1400-1411
-
-
Maki, K.C.1
Orloff, D.G.2
Nicholls, S.J.3
Dunbar, R.L.4
Roth, E.M.5
Curcio, D.6
Johnson, J.7
Kling, D.8
Davidson, M.H.9
-
23
-
-
80051784104
-
Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial)
-
1:CAS:528:DC%2BC3MXhtVajtrbF 21683321
-
Bays HE, Ballantyne CM, Kastelein JJ, Isaacsohn JL, Braeckman RA, Soni PN. Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial). Am J Cardiol. 2011;108:682-90.
-
(2011)
Am J Cardiol
, vol.108
, pp. 682-690
-
-
Bays, H.E.1
Ballantyne, C.M.2
Kastelein, J.J.3
Isaacsohn, J.L.4
Braeckman, R.A.5
Soni, P.N.6
-
24
-
-
84866124338
-
Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study)
-
1:CAS:528:DC%2BC38XhtVyktL7E 22819432
-
Ballantyne CM, Bays HE, Kastelein JJ, Stein E, Isaacsohn JL, Braeckman RA, Soni PN. Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study). Am J Cardiol. 2012;110:984-92.
-
(2012)
Am J Cardiol
, vol.110
, pp. 984-992
-
-
Ballantyne, C.M.1
Bays, H.E.2
Kastelein, J.J.3
Stein, E.4
Isaacsohn, J.L.5
Braeckman, R.A.6
Soni, P.N.7
-
26
-
-
84923088118
-
Fish oil supplements in New Zealand are highly oxidised and do not meet label content of n-3 PUFA
-
1:CAS:528:DC%2BC2MXhtFGgu7fM 25604397 4300506
-
Albert BB, Derraik JG, Cameron-Smith D, Hofman PL, Tumanov S, Villas-Boas SG, Garg ML, Cutfield WS. Fish oil supplements in New Zealand are highly oxidised and do not meet label content of n-3 PUFA. Sci Rep. 2015;5:7928.
-
(2015)
Sci Rep
, vol.5
, pp. 7928
-
-
Albert, B.B.1
Derraik, J.G.2
Cameron-Smith, D.3
Hofman, P.L.4
Tumanov, S.5
Villas-Boas, S.G.6
Garg, M.L.7
Cutfield, W.S.8
-
27
-
-
79960814823
-
Long chain omega-3 dietary supplements: A review of the National Library of Medicine Herbal Supplement Database
-
1:CAS:528:DC%2BC3MXptlCjs70%3D 21787228
-
Zargar A, Ito MK. Long chain omega-3 dietary supplements: a review of the National Library of Medicine Herbal Supplement Database. Metab Syndr Relat Disord. 2011;9:255-71.
-
(2011)
Metab Syndr Relat Disord
, vol.9
, pp. 255-271
-
-
Zargar, A.1
Ito, M.K.2
-
28
-
-
85027956925
-
Triglycerides and cardiovascular disease: A scientific statement from the American Heart Association
-
21502576
-
Miller M, Stone NJ, Ballantyne C, Bittner V, Criqui MH, Ginsberg HN, Goldberg AC, Howard WJ, Jacobson MS, Kris-Etherton PM, et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2011;123:2292-333.
-
(2011)
Circulation
, vol.123
, pp. 2292-2333
-
-
Miller, M.1
Stone, N.J.2
Ballantyne, C.3
Bittner, V.4
Criqui, M.H.5
Ginsberg, H.N.6
Goldberg, A.C.7
Howard, W.J.8
Jacobson, M.S.9
Kris-Etherton, P.M.10
-
29
-
-
0037126526
-
Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report
-
Grundy SM, Becker D, Clark LT, Cooper RS, Denke MA, Howard JW, Hunninghake DB, Illingwirth DR, Luepker RV. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143-421.
-
(2002)
Circulation
, vol.106
, pp. 3143-3421
-
-
Grundy, S.M.1
Becker, D.2
Clark, L.T.3
Cooper, R.S.4
Denke, M.A.5
Howard, J.W.6
Hunninghake, D.B.7
Illingwirth, D.R.8
Luepker, R.V.9
-
30
-
-
84860144206
-
American Association of Clinical Endocrinologists' guidelines for management of dyslipidemia and prevention of atherosclerosis
-
22522068
-
Jellinger PS, Smith DA, Mehta AE, Ganda O, Handelsman Y, Rodbard HW, Shepherd MD, Seibel JA. American Association of Clinical Endocrinologists' guidelines for management of dyslipidemia and prevention of atherosclerosis. Endocr Pract. 2012;18 Suppl 1:1-78.
-
(2012)
Endocr Pract
, vol.18
, pp. 1-78
-
-
Jellinger, P.S.1
Smith, D.A.2
Mehta, A.E.3
Ganda, O.4
Handelsman, Y.5
Rodbard, H.W.6
Shepherd, M.D.7
Seibel, J.A.8
-
31
-
-
84866146620
-
Evaluation and treatment of hypertriglyceridemia: An Endocrine Society clinical practice guideline
-
1:CAS:528:DC%2BC38XhtlymurbF 22962670 3431581
-
Berglund L, Brunzell JD, Goldberg AC, Goldberg IJ, Sacks F, Murad MH, Stalenhoef AF. Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2012;97:2969-89.
-
(2012)
J Clin Endocrinol Metab
, vol.97
, pp. 2969-2989
-
-
Berglund, L.1
Brunzell, J.D.2
Goldberg, A.C.3
Goldberg, I.J.4
Sacks, F.5
Murad, M.H.6
Stalenhoef, A.F.7
-
32
-
-
84892649479
-
Standards of medical care in diabetes 2014
-
Association AD. Standards of medical care in diabetes 2014. Diabetes Care. 2014;37 Suppl 1:S14-80.
-
(2014)
Diabetes Care
, vol.37
, pp. S14-S80
-
-
Association, A.D.1
-
33
-
-
79958148945
-
Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: Evidence and guidance for management
-
1:CAS:528:DC%2BC3MXntF2ht7k%3D 21531743 3105250
-
Chapman MJ, Ginsberg HN, Amarenco P, Andreotti F, Boren J, Catapano AL, Descamps OS, Fisher E, Kovanen PT, Kuivenhoven JA, et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J. 2011;32:1345-61.
-
(2011)
Eur Heart J
, vol.32
, pp. 1345-1361
-
-
Chapman, M.J.1
Ginsberg, H.N.2
Amarenco, P.3
Andreotti, F.4
Boren, J.5
Catapano, A.L.6
Descamps, O.S.7
Fisher, E.8
Kovanen, P.T.9
Kuivenhoven, J.A.10
-
34
-
-
79960205374
-
ESC/EAS guidelines for the management of dyslipidaemias. The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)
-
1:CAS:528:DC%2BC3MXptVyrtbo%3D 21882396
-
Catapano AL, Reiner Z, De Backer G, Graham I, Taskinen MR, Wiklund O, Agewall S, Alegria E, Chapman M, Durrington P, et al. ESC/EAS guidelines for the management of dyslipidaemias. The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis. 2011;217:3-46.
-
(2011)
Atherosclerosis
, vol.217
, pp. 3-46
-
-
Catapano, A.L.1
Reiner, Z.2
De Backer, G.3
Graham, I.4
Taskinen, M.R.5
Wiklund, O.6
Agewall, S.7
Alegria, E.8
Chapman, M.9
Durrington, P.10
-
35
-
-
41449110020
-
Prescription omega-3 fatty acids and their lipid effects: Physiologic mechanisms of action and clinical implications
-
1:CAS:528:DC%2BD1cXjtFOisrs%3D 18327998
-
Bays HE, Tighe AP, Sadovsky R, Davidson MH. Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications. Expert Rev Cardiovasc Ther. 2008;6:391-409.
-
(2008)
Expert Rev Cardiovasc Ther
, vol.6
, pp. 391-409
-
-
Bays, H.E.1
Tighe, A.P.2
Sadovsky, R.3
Davidson, M.H.4
-
36
-
-
13444309332
-
Hepatic farnesyl diphosphate synthase expression is suppressed by polyunsaturated fatty acids
-
15473864 1134755
-
Le Jossic-Corcos C, Gonthier C, Zaghini I, Logette E, Shechter I, Bournot P. Hepatic farnesyl diphosphate synthase expression is suppressed by polyunsaturated fatty acids. Biochem J. 2005;385:787-94.
-
(2005)
Biochem J
, vol.385
, pp. 787-794
-
-
Le Jossic-Corcos, C.1
Gonthier, C.2
Zaghini, I.3
Logette, E.4
Shechter, I.5
Bournot, P.6
-
37
-
-
0032568557
-
Regulation of sterol regulatory element binding proteins in livers of fasted and refed mice
-
1:CAS:528:DyaK1cXjtlKhtbY%3D 9600904 27572
-
Horton JD, Bashmakov Y, Shimomura I, Shimano H. Regulation of sterol regulatory element binding proteins in livers of fasted and refed mice. Proc Natl Acad Sci U S A. 1998;95:5987-92.
-
(1998)
Proc Natl Acad Sci U S A
, vol.95
, pp. 5987-5992
-
-
Horton, J.D.1
Bashmakov, Y.2
Shimomura, I.3
Shimano, H.4
-
38
-
-
33746040070
-
Why do omega-3 fatty acids lower serum triglycerides?
-
1:CAS:528:DC%2BD28Xms1yrtb0%3D 16832161
-
Harris WS, Bulchandani D. Why do omega-3 fatty acids lower serum triglycerides? Curr Opin Lipidol. 2006;17:387-93.
-
(2006)
Curr Opin Lipidol
, vol.17
, pp. 387-393
-
-
Harris, W.S.1
Bulchandani, D.2
-
39
-
-
0038281520
-
Omega-3 fatty acid supplementation accelerates chylomicron triglyceride clearance
-
12562865
-
Park Y, Harris WS. Omega-3 fatty acid supplementation accelerates chylomicron triglyceride clearance. J Lipid Res. 2003;44:455-63.
-
(2003)
J Lipid Res
, vol.44
, pp. 455-463
-
-
Park, Y.1
Harris, W.S.2
-
40
-
-
0035988357
-
Dietary long-chain n-3 PUFAs increase LPL gene expression in adipose tissue of subjects with an atherogenic lipoprotein phenotype
-
1:CAS:528:DC%2BD38XksFWgs78%3D 12032174
-
Khan S, Minihane AM, Talmud PJ, Wright JW, Murphy MC, Williams CM, Griffin BA. Dietary long-chain n-3 PUFAs increase LPL gene expression in adipose tissue of subjects with an atherogenic lipoprotein phenotype. J Lipid Res. 2002;43:979-85.
-
(2002)
J Lipid Res
, vol.43
, pp. 979-985
-
-
Khan, S.1
Minihane, A.M.2
Talmud, P.J.3
Wright, J.W.4
Murphy, M.C.5
Williams, C.M.6
Griffin, B.A.7
-
41
-
-
84856179128
-
Effects of eicosapentaenoic acid and docosahexaenoic acid on low-density lipoprotein cholesterol and other lipids: A review
-
22264569
-
Jacobson TA, Glickstein SB, Rowe JD, Soni PN. Effects of eicosapentaenoic acid and docosahexaenoic acid on low-density lipoprotein cholesterol and other lipids: a review. J Clin Lipidol. 2012;6:5-18.
-
(2012)
J Clin Lipidol
, vol.6
, pp. 5-18
-
-
Jacobson, T.A.1
Glickstein, S.B.2
Rowe, J.D.3
Soni, P.N.4
-
42
-
-
81155139591
-
Effects of eicosapentaenoic acid versus docosahexaenoic acid on serum lipids: A systematic review and meta-analysis
-
1:CAS:528:DC%2BC3MXhsVaht7vN 21975919
-
Wei MY, Jacobson TA. Effects of eicosapentaenoic acid versus docosahexaenoic acid on serum lipids: a systematic review and meta-analysis. Curr Atheroscler Rep. 2011;13:474-83.
-
(2011)
Curr Atheroscler Rep
, vol.13
, pp. 474-483
-
-
Wei, M.Y.1
Jacobson, T.A.2
-
43
-
-
84888286731
-
Omega-3 fatty acids: New insights into the pharmacology and biology of docosahexaenoic acid, docosapentaenoic acid, and eicosapentaenoic acid
-
1:CAS:528:DC%2BC3sXhslOmtrjN 24184945
-
Davidson MH. Omega-3 fatty acids: new insights into the pharmacology and biology of docosahexaenoic acid, docosapentaenoic acid, and eicosapentaenoic acid. Curr Opin Lipidol. 2013;24:467-74.
-
(2013)
Curr Opin Lipidol
, vol.24
, pp. 467-474
-
-
Davidson, M.H.1
-
44
-
-
84955333550
-
The effect of omega-3 carboxylic acids on apolipoprotein CIII containing lipoproteins in moderate to severe hypertriglyceridemia
-
A16864
-
Morton A, Furtado J, Amerine W, Kling D, Davidson M, Sacks F. The effect of omega-3 carboxylic acids on apolipoprotein CIII containing lipoproteins in moderate to severe hypertriglyceridemia. Circulation. 2014;130 Suppl 1, A16864.
-
(2014)
Circulation
, vol.130
-
-
Morton, A.1
Furtado, J.2
Amerine, W.3
Kling, D.4
Davidson, M.5
Sacks, F.6
-
45
-
-
79956014824
-
Complexities of plasma apolipoprotein C-III metabolism
-
1:CAS:528:DC%2BC3MXmslOitr0%3D 21421846 3090227
-
Sacks FM, Zheng C, Cohn JS. Complexities of plasma apolipoprotein C-III metabolism. J Lipid Res. 2011;52:1067-70.
-
(2011)
J Lipid Res
, vol.52
, pp. 1067-1070
-
-
Sacks, F.M.1
Zheng, C.2
Cohn, J.S.3
-
46
-
-
84874052886
-
Icosapent ethyl, a pure ethyl ester of eicosapentaenoic acid: Effects on circulating markers of inflammation from the MARINE and ANCHOR studies
-
1:CAS:528:DC%2BC3sXhsl2ntL%2FE 23325450 3572383
-
Bays HE, Ballantyne CM, Braeckman RA, Stirtan WG, Soni PN. Icosapent ethyl, a pure ethyl ester of eicosapentaenoic acid: effects on circulating markers of inflammation from the MARINE and ANCHOR studies. Am J Cardiovasc Drugs. 2013;13:37-46.
-
(2013)
Am J Cardiovasc Drugs
, vol.13
, pp. 37-46
-
-
Bays, H.E.1
Ballantyne, C.M.2
Braeckman, R.A.3
Stirtan, W.G.4
Soni, P.N.5
-
47
-
-
84855358563
-
Antiarrhythmic effects of free polyunsaturated fatty acids in an experimental model of LQT2 and LQT3 due to suppression of early afterdepolarizations and reduction of spatial and temporal dispersion of repolarization
-
21459164
-
Milberg P, Frommeyer G, Kleideiter A, Fischer A, Osada N, Breithardt G, Fehr M, Eckardt L. Antiarrhythmic effects of free polyunsaturated fatty acids in an experimental model of LQT2 and LQT3 due to suppression of early afterdepolarizations and reduction of spatial and temporal dispersion of repolarization. Heart Rhythm. 2011;8:1492-500.
-
(2011)
Heart Rhythm
, vol.8
, pp. 1492-1500
-
-
Milberg, P.1
Frommeyer, G.2
Kleideiter, A.3
Fischer, A.4
Osada, N.5
Breithardt, G.6
Fehr, M.7
Eckardt, L.8
-
48
-
-
84872368428
-
Omega-3 polyunsaturated fatty acid has an anti-oxidant effect via the Nrf-2/HO-1 pathway in 3T3-L1 adipocytes
-
1:CAS:528:DC%2BC38XhvV2rs7vP 23131562
-
Kusunoki C, Yang L, Yoshizaki T, Nakagawa F, Ishikado A, Kondo M, Morino K, Sekine O, Ugi S, Nishio Y, et al. Omega-3 polyunsaturated fatty acid has an anti-oxidant effect via the Nrf-2/HO-1 pathway in 3T3-L1 adipocytes. Biochem Biophys Res Commun. 2013;430:225-30.
-
(2013)
Biochem Biophys Res Commun
, vol.430
, pp. 225-230
-
-
Kusunoki, C.1
Yang, L.2
Yoshizaki, T.3
Nakagawa, F.4
Ishikado, A.5
Kondo, M.6
Morino, K.7
Sekine, O.8
Ugi, S.9
Nishio, Y.10
-
49
-
-
0036842041
-
Eicosapentaenoic acid improves endothelial function in hypertriglyceridemic subjects despite increased lipid oxidizability
-
12449445
-
Okumura T, Fujioka Y, Morimoto S, Tsuboi S, Masai M, Tsujino T, Ohyanagi M, Iwasaki T. Eicosapentaenoic acid improves endothelial function in hypertriglyceridemic subjects despite increased lipid oxidizability. Am J Med Sci. 2002;324:247-53.
-
(2002)
Am J Med Sci
, vol.324
, pp. 247-253
-
-
Okumura, T.1
Fujioka, Y.2
Morimoto, S.3
Tsuboi, S.4
Masai, M.5
Tsujino, T.6
Ohyanagi, M.7
Iwasaki, T.8
-
50
-
-
7044247219
-
Docosahexaenoic acid restores endothelial function in children with hyperlipidemia: Results from the EARLY study
-
1:CAS:528:DC%2BD2MXhtVeqtQ%3D%3D 15624283
-
Engler MM, Engler MB, Malloy M, Chiu E, Besio D, Paul S, Stuehlinger M, Morrow J, Ridker P, Rifai N, Mietus-Snyder M. Docosahexaenoic acid restores endothelial function in children with hyperlipidemia: results from the EARLY study. Int J Clin Pharmacol Ther. 2004;42:672-9.
-
(2004)
Int J Clin Pharmacol Ther
, vol.42
, pp. 672-679
-
-
Engler, M.M.1
Engler, M.B.2
Malloy, M.3
Chiu, E.4
Besio, D.5
Paul, S.6
Stuehlinger, M.7
Morrow, J.8
Ridker, P.9
Rifai, N.10
Mietus-Snyder, M.11
-
51
-
-
84879467569
-
Beneficial effects of omega-3 fatty acids on low density lipoprotein particle size in patients with type 2 diabetes already under statin therapy
-
23807924 3689018
-
Lee MW, Park JK, Hong JW, Kim KJ, Shin DY, Ahn CW, Song YD, Cho HK, Park SW, Lee EJ. Beneficial effects of omega-3 fatty acids on low density lipoprotein particle size in patients with type 2 diabetes already under statin therapy. Diabetes Metab J. 2013;37:207-11.
-
(2013)
Diabetes Metab J
, vol.37
, pp. 207-211
-
-
Lee, M.W.1
Park, J.K.2
Hong, J.W.3
Kim, K.J.4
Shin, D.Y.5
Ahn, C.W.6
Song, Y.D.7
Cho, H.K.8
Park, S.W.9
Lee, E.J.10
-
52
-
-
79959441185
-
Early impact of prescription omega-3 fatty acids on platelet biomarkers in patients with coronary artery disease and hypertriglyceridemia
-
1:CAS:528:DC%2BC3MXotlyrsro%3D 21701167
-
Serebruany VL, Miller M, Pokov AN, Lynch D, Jensen JK, Hallen J, Atar D. Early impact of prescription omega-3 fatty acids on platelet biomarkers in patients with coronary artery disease and hypertriglyceridemia. Cardiology. 2011;118:187-94.
-
(2011)
Cardiology
, vol.118
, pp. 187-194
-
-
Serebruany, V.L.1
Miller, M.2
Pokov, A.N.3
Lynch, D.4
Jensen, J.K.5
Hallen, J.6
Atar, D.7
-
53
-
-
0037211979
-
Effects of purified eicosapentaenoic acid and docosahexaenoic acid on platelet, fibrinolytic and vascular function in hypertensive type 2 diabetic patients
-
1:CAS:528:DC%2BD38XptlGjsrw%3D 12482554
-
Woodman RJ, Mori TA, Burke V, Puddey IB, Barden A, Watts GF, Beilin LJ. Effects of purified eicosapentaenoic acid and docosahexaenoic acid on platelet, fibrinolytic and vascular function in hypertensive type 2 diabetic patients. Atherosclerosis. 2003;166:85-93.
-
(2003)
Atherosclerosis
, vol.166
, pp. 85-93
-
-
Woodman, R.J.1
Mori, T.A.2
Burke, V.3
Puddey, I.B.4
Barden, A.5
Watts, G.F.6
Beilin, L.J.7
-
54
-
-
0032858328
-
Docosahexaenoic acid but not eicosapentaenoic acid lowers ambulatory blood pressure and heart rate in humans
-
1:CAS:528:DyaK1MXlvFGmtbw%3D 10454450
-
Mori TA, Bao DQ, Burke V, Puddey IB, Beilin LJ. Docosahexaenoic acid but not eicosapentaenoic acid lowers ambulatory blood pressure and heart rate in humans. Hypertension. 1999;34:253-60.
-
(1999)
Hypertension
, vol.34
, pp. 253-260
-
-
Mori, T.A.1
Bao, D.Q.2
Burke, V.3
Puddey, I.B.4
Beilin, L.J.5
-
55
-
-
2442445051
-
Differential eicosapentaenoic acid elevations and altered cardiovascular disease risk factor responses after supplementation with docosahexaenoic acid in postmenopausal women receiving and not receiving hormone replacement therapy
-
1:CAS:528:DC%2BD2cXjs1ygsL0%3D 15113713
-
Stark KD, Holub BJ. Differential eicosapentaenoic acid elevations and altered cardiovascular disease risk factor responses after supplementation with docosahexaenoic acid in postmenopausal women receiving and not receiving hormone replacement therapy. Am J Clin Nutr. 2004;79:765-73.
-
(2004)
Am J Clin Nutr
, vol.79
, pp. 765-773
-
-
Stark, K.D.1
Holub, B.J.2
-
56
-
-
34247105669
-
Low-dose docosahexaenoic acid lowers diastolic blood pressure in middle-aged men and women
-
1:CAS:528:DC%2BD2sXktVSltbk%3D 17374663
-
Theobald HE, Goodall AH, Sattar N, Talbot DC, Chowienczyk PJ, Sanders TA. Low-dose docosahexaenoic acid lowers diastolic blood pressure in middle-aged men and women. J Nutr. 2007;137:973-8.
-
(2007)
J Nutr
, vol.137
, pp. 973-978
-
-
Theobald, H.E.1
Goodall, A.H.2
Sattar, N.3
Talbot, D.C.4
Chowienczyk, P.J.5
Sanders, T.A.6
-
57
-
-
84953911431
-
DHA effects in brain development and function
-
Lauritzen L, Brambilla P, Mazzocchi A, Harslof LB, Ciappolino V, Agostoni C. DHA effects in brain development and function. Nutrients 2016; 8
-
(2016)
Nutrients
, vol.8
-
-
Lauritzen, L.1
Brambilla, P.2
Mazzocchi, A.3
Harslof, L.B.4
Ciappolino, V.5
Agostoni, C.6
-
58
-
-
4043094921
-
Very long chain N-3 fatty acids intake and carotid atherosclerosis: An epidemiological study evaluated by ultrasonography
-
1:CAS:528:DC%2BD2cXmslers7Y%3D 15306187
-
Hino A, Adachi H, Toyomasu K, Yoshida N, Enomoto M, Hiratsuka A, Hirai Y, Satoh A, Imaizumi T. Very long chain N-3 fatty acids intake and carotid atherosclerosis: an epidemiological study evaluated by ultrasonography. Atherosclerosis. 2004;176:145-9.
-
(2004)
Atherosclerosis
, vol.176
, pp. 145-149
-
-
Hino, A.1
Adachi, H.2
Toyomasu, K.3
Yoshida, N.4
Enomoto, M.5
Hiratsuka, A.6
Hirai, Y.7
Satoh, A.8
Imaizumi, T.9
-
59
-
-
77956225520
-
Eicosapentaenoic acid (EPA) from highly concentrated n-3 fatty acid ethyl esters is incorporated into advanced atherosclerotic plaques and higher plaque EPA is associated with decreased plaque inflammation and increased stability
-
1:CAS:528:DC%2BC3cXhtFams77K 20542512
-
Cawood AL, Ding R, Napper FL, Young RH, Williams JA, Ward MJ, Gudmundsen O, Vige R, Payne SP, Ye S, et al. Eicosapentaenoic acid (EPA) from highly concentrated n-3 fatty acid ethyl esters is incorporated into advanced atherosclerotic plaques and higher plaque EPA is associated with decreased plaque inflammation and increased stability. Atherosclerosis. 2010;212:252-9.
-
(2010)
Atherosclerosis
, vol.212
, pp. 252-259
-
-
Cawood, A.L.1
Ding, R.2
Napper, F.L.3
Young, R.H.4
Williams, J.A.5
Ward, M.J.6
Gudmundsen, O.7
Vige, R.8
Payne, S.P.9
Ye, S.10
-
60
-
-
84906259943
-
Triglycerides and cardiovascular disease
-
1:CAS:528:DC%2BC2cXhtlOrtLnK 25131982
-
Nordestgaard BG, Varbo A. Triglycerides and cardiovascular disease. Lancet. 2014;384:626-35.
-
(2014)
Lancet
, vol.384
, pp. 626-635
-
-
Nordestgaard, B.G.1
Varbo, A.2
-
61
-
-
0029082703
-
Serum fatty acids and the risk of coronary heart disease
-
1:STN:280:DyaK2MvgslKjtw%3D%3D 7677125
-
Simon JA, Hodgkins ML, Browner WS, Neuhaus JM, Bernert JJ, Hulley SB. Serum fatty acids and the risk of coronary heart disease. Am J Epidemiol. 1995;142:469-76.
-
(1995)
Am J Epidemiol
, vol.142
, pp. 469-476
-
-
Simon, J.A.1
Hodgkins, M.L.2
Browner, W.S.3
Neuhaus, J.M.4
Bernert, J.J.5
Hulley, S.B.6
-
62
-
-
47249110902
-
Blood concentrations of individual long-chain n-3 fatty acids and risk of nonfatal myocardial infarction
-
1:CAS:528:DC%2BD1cXoslyltrw%3D 18614744
-
Sun Q, Ma J, Campos H, Rexrode KM, Albert CM, Mozaffarian D, Hu FB. Blood concentrations of individual long-chain n-3 fatty acids and risk of nonfatal myocardial infarction. Am J Clin Nutr. 2008;88:216-23.
-
(2008)
Am J Clin Nutr
, vol.88
, pp. 216-223
-
-
Sun, Q.1
Ma, J.2
Campos, H.3
Rexrode, K.M.4
Albert, C.M.5
Mozaffarian, D.6
Hu, F.B.7
-
63
-
-
80052272215
-
Impact of omega-3 polyunsaturated fatty acids on coronary plaque instability: An integrated backscatter intravascular ultrasound study
-
1:CAS:528:DC%2BC3MXhtFeht7zM 21684546
-
Amano T, Matsubara T, Uetani T, Kato M, Kato B, Yoshida T, Harada K, Kumagai S, Kunimura A, Shinbo Y, et al. Impact of omega-3 polyunsaturated fatty acids on coronary plaque instability: an integrated backscatter intravascular ultrasound study. Atherosclerosis. 2011;218:110-6.
-
(2011)
Atherosclerosis
, vol.218
, pp. 110-116
-
-
Amano, T.1
Matsubara, T.2
Uetani, T.3
Kato, M.4
Kato, B.5
Yoshida, T.6
Harada, K.7
Kumagai, S.8
Kunimura, A.9
Shinbo, Y.10
-
64
-
-
0028177432
-
Plasma essential fatty acids, cigarette smoking, and dietary antioxidants in peripheral arterial disease. A population-based case-control study
-
1:STN:280:DyaK2c7mvFWmtg%3D%3D 8123654
-
Leng GC, Horrobin DF, Fowkes FG, Smith FB, Lowe GD, Donnan PT, Ells K. Plasma essential fatty acids, cigarette smoking, and dietary antioxidants in peripheral arterial disease. A population-based case-control study. Arterioscler Thromb. 1994;14:471-8.
-
(1994)
Arterioscler Thromb
, vol.14
, pp. 471-478
-
-
Leng, G.C.1
Horrobin, D.F.2
Fowkes, F.G.3
Smith, F.B.4
Lowe, G.D.5
Donnan, P.T.6
Ells, K.7
-
65
-
-
0033668024
-
Involvement of lipoxygenase pathway in docosapentaenoic acid-induced inhibition of platelet aggregation
-
1:CAS:528:DC%2BD3cXnvVyhsb0%3D 11085354
-
Akiba S, Murata T, Kitatani K, Sato T. Involvement of lipoxygenase pathway in docosapentaenoic acid-induced inhibition of platelet aggregation. Biol Pharm Bull. 2000;23:1293-7.
-
(2000)
Biol Pharm Bull
, vol.23
, pp. 1293-1297
-
-
Akiba, S.1
Murata, T.2
Kitatani, K.3
Sato, T.4
-
66
-
-
33646823117
-
Docosahexaenoic acid enrichment can reduce L929 cell necrosis induced by tumor necrosis factor
-
1:CAS:528:DC%2BD28XltFGjt74%3D 16698313
-
Kishida E, Tajiri M, Masuzawa Y. Docosahexaenoic acid enrichment can reduce L929 cell necrosis induced by tumor necrosis factor. Biochim Biophys Acta. 2006;1761:454-62.
-
(2006)
Biochim Biophys Acta
, vol.1761
, pp. 454-462
-
-
Kishida, E.1
Tajiri, M.2
Masuzawa, Y.3
-
67
-
-
0036325388
-
Regulatory effects of HMG CoA reductase inhibitor and fish oils on apolipoprotein B-100 kinetics in insulin-resistant obese male subjects with dyslipidemia
-
1:CAS:528:DC%2BD38XlvFKiur8%3D 12145148
-
Chan DC, Watts GF, Barrett PH, Beilin LJ, Redgrave TG, Mori TA. Regulatory effects of HMG CoA reductase inhibitor and fish oils on apolipoprotein B-100 kinetics in insulin-resistant obese male subjects with dyslipidemia. Diabetes. 2002;51:2377-86.
-
(2002)
Diabetes
, vol.51
, pp. 2377-2386
-
-
Chan, D.C.1
Watts, G.F.2
Barrett, P.H.3
Beilin, L.J.4
Redgrave, T.G.5
Mori, T.A.6
-
68
-
-
84870302077
-
A novel omega-3 free fatty acid formulation has dramatically improved bioavailability during a low-fat diet compared with omega-3-acid ethyl esters: The ECLIPSE (Epanova® compared to Lovaza® in a pharmacokinetic single-dose evaluation) study
-
23312053
-
Davidson MH, Johnson J, Rooney MW, Kyle ML, Kling DF. A novel omega-3 free fatty acid formulation has dramatically improved bioavailability during a low-fat diet compared with omega-3-acid ethyl esters: the ECLIPSE (Epanova® compared to Lovaza® in a pharmacokinetic single-dose evaluation) study. J Clin Lipidol. 2012;6:573-84.
-
(2012)
J Clin Lipidol
, vol.6
, pp. 573-584
-
-
Davidson, M.H.1
Johnson, J.2
Rooney, M.W.3
Kyle, M.L.4
Kling, D.F.5
-
69
-
-
0027994257
-
The synthesis of fatty acid ethyl ester by carboxylester lipase
-
1:CAS:528:DyaK2cXlsFWqu7c%3D 8076651
-
Tsujita T, Okuda H. The synthesis of fatty acid ethyl ester by carboxylester lipase. Eur J Biochem. 1994;224:57-62.
-
(1994)
Eur J Biochem
, vol.224
, pp. 57-62
-
-
Tsujita, T.1
Okuda, H.2
-
70
-
-
0036915534
-
Carboxyl ester lipase: Structure-function relationship and physiological role in lipoprotein metabolism and atherosclerosis
-
1:CAS:528:DC%2BD38XpslGjsr8%3D 12454261
-
Hui DY, Howles PN. Carboxyl ester lipase: structure-function relationship and physiological role in lipoprotein metabolism and atherosclerosis. J Lipid Res. 2002;43:2017-30.
-
(2002)
J Lipid Res
, vol.43
, pp. 2017-2030
-
-
Hui, D.Y.1
Howles, P.N.2
-
71
-
-
0029616284
-
Digestion and lymphatic transport of eicosapentaenoic and docosahexaenoic acids given in the form of triacylglycerol, free acid and ethyl ester in rats
-
8541338
-
Ikeda I, Sasaki E, Yasunami H, Nomiyama S, Nakayama M, Sugano M, Imaizumi K, Yazawa K. Digestion and lymphatic transport of eicosapentaenoic and docosahexaenoic acids given in the form of triacylglycerol, free acid and ethyl ester in rats. Biochim Biophys Acta. 1995;1259:297-304.
-
(1995)
Biochim Biophys Acta
, vol.1259
, pp. 297-304
-
-
Ikeda, I.1
Sasaki, E.2
Yasunami, H.3
Nomiyama, S.4
Nakayama, M.5
Sugano, M.6
Imaizumi, K.7
Yazawa, K.8
-
72
-
-
0025331290
-
[Comparative bioavailability of eicosapentaenoic acid and docasahexaenoic acid from triglycerides, free fatty acids and ethyl esters in volunteers]
-
1:CAS:528:DyaK3cXlslyisL8%3D 2144420
-
Beckermann B, Beneke M, Seitz I. [Comparative bioavailability of eicosapentaenoic acid and docasahexaenoic acid from triglycerides, free fatty acids and ethyl esters in volunteers]. Arzneimittelforschung. 1990;40:700-4.
-
(1990)
Arzneimittelforschung
, vol.40
, pp. 700-704
-
-
Beckermann, B.1
Beneke, M.2
Seitz, I.3
-
73
-
-
33749154105
-
Effects of omega-3 fatty acids on serum markers of cardiovascular disease risk: A systematic review
-
1:CAS:528:DC%2BD28XhtVajsr3L 16530201
-
Balk EM, Lichtenstein AH, Chung M, Kupelnick B, Chew P, Lau J. Effects of omega-3 fatty acids on serum markers of cardiovascular disease risk: a systematic review. Atherosclerosis. 2006;189:19-30.
-
(2006)
Atherosclerosis
, vol.189
, pp. 19-30
-
-
Balk, E.M.1
Lichtenstein, A.H.2
Chung, M.3
Kupelnick, B.4
Chew, P.5
Lau, J.6
-
74
-
-
84978851547
-
A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High Risk Patients with Hypertriglyceridemia and on Statin
-
Clinicaltrials.gov. (REDUCE-IT) Accessed: 24 Nov 2015
-
Clinicaltrials.gov. A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High Risk Patients With Hypertriglyceridemia and on Statin. The Primary Objective is to Evaluate the Effect of 4 g/Day AMR101 for Preventing the Occurrence of a First Major Cardiovascular Event. (REDUCE-IT). Available at: https://clinicaltrials.gov/ct2/show/NCT01492361. Accessed: 24 Nov 2015.
-
The Primary Objective Is to Evaluate the Effect of 4 G/Day AMR101 for Preventing the Occurrence of A First Major Cardiovascular Event
-
-
-
76
-
-
84055213533
-
Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: Summary report
-
Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents
-
Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics. 2011;128 Suppl 5:S213-56.
-
(2011)
Pediatrics
, vol.1285
, pp. S213-S256
-
-
-
77
-
-
84857933923
-
Impaired fetal growth and arterial wall thickening: A randomized trial of omega-3 supplementation
-
22351892
-
Skilton MR, Ayer JG, Harmer JA, Webb K, Leeder SR, Marks GB, Celermajer DS. Impaired fetal growth and arterial wall thickening: a randomized trial of omega-3 supplementation. Pediatrics. 2012;129:e698-703.
-
(2012)
Pediatrics
, vol.129
, pp. e698-e703
-
-
Skilton, M.R.1
Ayer, J.G.2
Harmer, J.A.3
Webb, K.4
Leeder, S.R.5
Marks, G.B.6
Celermajer, D.S.7
-
78
-
-
0038076490
-
Long chain polyunsaturated fatty acid supplementation in infant formula and blood pressure in later childhood: Follow up of a randomised controlled trial
-
1:CAS:528:DC%2BD3sXktlSrt7g%3D 12727766 153849
-
Forsyth JS, Willatts P, Agostoni C, Bissenden J, Casaer P, Boehm G. Long chain polyunsaturated fatty acid supplementation in infant formula and blood pressure in later childhood: follow up of a randomised controlled trial. BMJ. 2003;326:953.
-
(2003)
BMJ
, vol.326
, pp. 953
-
-
Forsyth, J.S.1
Willatts, P.2
Agostoni, C.3
Bissenden, J.4
Casaer, P.5
Boehm, G.6
-
79
-
-
84876672954
-
High intake of dietary long-chain omega-3 fatty acids is associated with lower blood pressure in children born with low birth weight: NHANES 2003-2008
-
1:CAS:528:DC%2BC3sXmtF2rtbg%3D 23460284
-
Skilton MR, Raitakari OT, Celermajer DS. High intake of dietary long-chain omega-3 fatty acids is associated with lower blood pressure in children born with low birth weight: NHANES 2003-2008. Hypertension. 2013;61:972-6.
-
(2013)
Hypertension
, vol.61
, pp. 972-976
-
-
Skilton, M.R.1
Raitakari, O.T.2
Celermajer, D.S.3
-
80
-
-
84878762553
-
The role of omega-3 polyunsaturated fatty acids supplementation in childhood: A review
-
1:CAS:528:DC%2BC3sXhtFSms7fN 23544707
-
Ciccone MM, Scicchitano P, Gesualdo M, Zito A, Carbonara S, Ricci G, Cortese F, Giordano P. The role of omega-3 polyunsaturated fatty acids supplementation in childhood: a review. Recent Pat Cardiovasc Drug Discov. 2013;8:42-55.
-
(2013)
Recent Pat Cardiovasc Drug Discov
, vol.8
, pp. 42-55
-
-
Ciccone, M.M.1
Scicchitano, P.2
Gesualdo, M.3
Zito, A.4
Carbonara, S.5
Ricci, G.6
Cortese, F.7
Giordano, P.8
-
81
-
-
77953012291
-
Omega-3 fatty acids in high-risk cardiovascular patients: A meta-analysis of randomized controlled trials
-
20525225 2894745
-
Filion KB, El Khoury F, Bielinski M, Schiller I, Dendukuri N, Brophy JM. Omega-3 fatty acids in high-risk cardiovascular patients: a meta-analysis of randomized controlled trials. BMC Cardiovasc Disord. 2010;10:24.
-
(2010)
BMC Cardiovasc Disord
, vol.10
, pp. 24
-
-
Filion, K.B.1
El Khoury, F.2
Bielinski, M.3
Schiller, I.4
Dendukuri, N.5
Brophy, J.M.6
-
82
-
-
33745063941
-
Study of the pharmacokinetic interaction between simvastatin and prescription omega-3-acid ethyl esters
-
1:CAS:528:DC%2BD28XntlWgtrw%3D 16809804
-
McKenney JM, Swearingen D, Di SM, Doyle R, Pantaleon C, Kling D, Shalwitz RA. Study of the pharmacokinetic interaction between simvastatin and prescription omega-3-acid ethyl esters. J Clin Pharmacol. 2006;46:785-91.
-
(2006)
J Clin Pharmacol
, vol.46
, pp. 785-791
-
-
McKenney, J.M.1
Swearingen, D.2
Di, S.M.3
Doyle, R.4
Pantaleon, C.5
Kling, D.6
Shalwitz, R.A.7
-
83
-
-
57549108116
-
Effect of omega-3-acid ethyl esters on steady-state plasma pharmacokinetics of atorvastatin in healthy adults
-
19006470
-
Di Spirito M, Morelli G, Doyle RT, Johnson J, McKenney J. Effect of omega-3-acid ethyl esters on steady-state plasma pharmacokinetics of atorvastatin in healthy adults. Expert Opin Pharmacother. 2008;9:2939-45.
-
(2008)
Expert Opin Pharmacother
, vol.9
, pp. 2939-2945
-
-
Di Spirito, M.1
Morelli, G.2
Doyle, R.T.3
Johnson, J.4
McKenney, J.5
-
84
-
-
77149180421
-
Rosuvastatin-associated adverse effects and drug-drug interactions in the clinical setting of dyslipidemia
-
1:CAS:528:DC%2BC3cXksFGiurw%3D 20104931
-
Kostapanos MS, Milionis HJ, Elisaf MS. Rosuvastatin-associated adverse effects and drug-drug interactions in the clinical setting of dyslipidemia. Am J Cardiovasc Drugs. 2010;10:11-28.
-
(2010)
Am J Cardiovasc Drugs
, vol.10
, pp. 11-28
-
-
Kostapanos, M.S.1
Milionis, H.J.2
Elisaf, M.S.3
-
85
-
-
0034762548
-
An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia
-
1:STN:280:DC%2BD3M3ms1SqtA%3D%3D 11303007 1729738
-
Durrington PN, Bhatnagar D, Mackness MI, Morgan J, Julier K, Khan MA, France M. An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia. Heart. 2001;85:544-8.
-
(2001)
Heart
, vol.85
, pp. 544-548
-
-
Durrington, P.N.1
Bhatnagar, D.2
Mackness, M.I.3
Morgan, J.4
Julier, K.5
Khan, M.A.6
France, M.7
-
86
-
-
75749115919
-
Effects of prescription omega-3-acid ethyl esters on non-high-density lipoprotein cholesterol when coadministered with escalating doses of atorvastatin
-
1:CAS:528:DC%2BC3cXisFCgtrg%3D 20118387 2813819
-
Bays HE, McKenney J, Maki KC, Doyle RT, Carter RN, Stein E. Effects of prescription omega-3-acid ethyl esters on non-high-density lipoprotein cholesterol when coadministered with escalating doses of atorvastatin. Mayo Clin Proc. 2010;85:122-8.
-
(2010)
Mayo Clin Proc
, vol.85
, pp. 122-128
-
-
Bays, H.E.1
McKenney, J.2
Maki, K.C.3
Doyle, R.T.4
Carter, R.N.5
Stein, E.6
-
87
-
-
33947113384
-
Safety considerations with omega-3 fatty acid therapy
-
1:CAS:528:DC%2BD2sXjtFGltL8%3D 17368277
-
Bays HE. Safety considerations with omega-3 fatty acid therapy. Am J Cardiol. 2007;99:35C-43C.
-
(2007)
Am J Cardiol
, vol.99
, pp. 35C-43C
-
-
Bays, H.E.1
-
88
-
-
33947181467
-
Expert opinion: Omega-3 fatty acids and bleeding - Cause for concern?
-
1:CAS:528:DC%2BD2sXjtFGltLw%3D 17368278
-
Harris WS. Expert opinion: omega-3 fatty acids and bleeding - cause for concern? Am J Cardiol. 2007;99:44C-6C.
-
(2007)
Am J Cardiol
, vol.99
, pp. 44C-46C
-
-
Harris, W.S.1
-
89
-
-
84978913530
-
Multiple-dose administration of a free-fatty acid formulation or EPA/DHA has no effect on the pharmacokinetics or pharmacodynamics of single-dose warfarin
-
Abstract T2284
-
Davidson MH, Marenco T, Honstein A, Johnson J, Kling D. Multiple-dose administration of a free-fatty acid formulation or EPA/DHA has no effect on the pharmacokinetics or pharmacodynamics of single-dose warfarin. In 2012 AAPS Annual Meeting and Exposition. Abstract T2284
-
2012 AAPS Annual Meeting and Exposition
-
-
Davidson, M.H.1
Marenco, T.2
Honstein, A.3
Johnson, J.4
Kling, D.5
-
90
-
-
84904059562
-
Phase 1 study of the effect of icosapent ethyl on warfarin pharmacokinetic and anticoagulation parameters
-
1:CAS:528:DC%2BC2cXntFOlurs%3D 24760401
-
Braeckman RA, Stirtan WG, Soni PN. Phase 1 study of the effect of icosapent ethyl on warfarin pharmacokinetic and anticoagulation parameters. Clin Drug Investig. 2014;34:449-56.
-
(2014)
Clin Drug Investig
, vol.34
, pp. 449-456
-
-
Braeckman, R.A.1
Stirtan, W.G.2
Soni, P.N.3
-
91
-
-
59549092689
-
Complementary and alternative medicine use among adults and children: United States, 2007
-
19361005
-
Barnes PM, Bloom B, Nahin RL. Complementary and alternative medicine use among adults and children: United States, 2007. Natl Health Stat Report. 2008;12:1-23.
-
(2008)
Natl Health Stat Report
, vol.12
, pp. 1-23
-
-
Barnes, P.M.1
Bloom, B.2
Nahin, R.L.3
-
92
-
-
0038488757
-
-
Omega-3 oil: fish or pills? No authors listed
-
Omega-3 oil: fish or pills? Consum Rep 2003;68:30-32. No authors listed.
-
(2003)
Consum Rep
, vol.68
, pp. 30-32
-
-
-
93
-
-
84914811260
-
Overview of prescription omega-3 fatty acid products for hypertriglyceridemia
-
25387209
-
Weintraub HS. Overview of prescription omega-3 fatty acid products for hypertriglyceridemia. Postgrad Med. 2014;126:7-18.
-
(2014)
Postgrad Med
, vol.126
, pp. 7-18
-
-
Weintraub, H.S.1
-
94
-
-
33750141751
-
Fish intake, contaminants, and human health: Evaluating the risks and the benefits
-
1:CAS:528:DC%2BD28XhtFWmt7%2FF 17047219
-
Mozaffarian D, Rimm EB. Fish intake, contaminants, and human health: evaluating the risks and the benefits. JAMA. 2006;296:1885-99.
-
(2006)
JAMA
, vol.296
, pp. 1885-1899
-
-
Mozaffarian, D.1
Rimm, E.B.2
-
95
-
-
0037137299
-
Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease
-
12438303
-
Kris-Etherton PM, Harris WS, Appel LJ. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation. 2002;106:2747-57.
-
(2002)
Circulation
, vol.106
, pp. 2747-2757
-
-
Kris-Etherton, P.M.1
Harris, W.S.2
Appel, L.J.3
-
96
-
-
0036202812
-
Clinical nutrition: 4. Omega-3 fatty acids in cardiovascular care
-
11898942 99405
-
Holub BJ. Clinical nutrition: 4. Omega-3 fatty acids in cardiovascular care. CMAJ. 2002;166:608-15.
-
(2002)
CMAJ
, vol.166
, pp. 608-615
-
-
Holub, B.J.1
-
97
-
-
84895072502
-
Nutraceuticals and dyslipidaemia: Beyond the common therapeutics
-
1:CAS:528:DC%2BC2cXivVCjuw%3D%3D
-
Scicchitano P, Cameli M, Maiello M, Modesti P, Muiesan M, Novo S, Palmiero P, Saba P, Pedrinelli R, Ciccone M. Nutraceuticals and dyslipidaemia: beyond the common therapeutics. J Funct Foods. 2014;6:11-32.
-
(2014)
J Funct Foods
, vol.6
, pp. 11-32
-
-
Scicchitano, P.1
Cameli, M.2
Maiello, M.3
Modesti, P.4
Muiesan, M.5
Novo, S.6
Palmiero, P.7
Saba, P.8
Pedrinelli, R.9
Ciccone, M.10
|